Thermo Fisher Scientific Inc. $TMO Shares Sold by Fiduciary Alliance LLC

Key Points

• Fiduciary Alliance LLC reduced its stake in Thermo Fisher Scientific by 67.6% during the second quarter, owning only 502 shares, valued at approximately $204,000 by the end of the quarter.
• CEO Marc N. Casper sold 400 shares at an average price of $500.50, resulting in a total value of $200,200, which marked a 0.35% decrease in his ownership.
• Thermo Fisher Scientific recently announced a $0.43 quarterly dividend, representing an annualized yield of 0.4%, with a dividend payout ratio of 9.95%.

Fiduciary Alliance LLC trimmed its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 67.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 502 shares of the medical research company's stock after selling 1,046 shares during the quarter. Fiduciary Alliance LLC's holdings in Thermo Fisher Scientific were worth $204,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of TMO. Vanguard Group Inc. grew its holdings in shares of Thermo Fisher Scientific by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company's stock worth $16,659,627,000 after acquiring an additional 230,382 shares during the period. Amundi boosted its position in Thermo Fisher Scientific by 5.9% during the first quarter. Amundi now owns 3,029,044 shares of the medical research company's stock worth $1,426,316,000 after purchasing an additional 168,197 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in Thermo Fisher Scientific by 4.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company's stock worth $1,455,774,000 after purchasing an additional 115,463 shares in the last quarter. Pictet Asset Management Holding SA boosted its position in Thermo Fisher Scientific by 7.2% during the first quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company's stock worth $1,432,816,000 after purchasing an additional 193,378 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Thermo Fisher Scientific by 13.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company's stock worth $1,368,859,000 after purchasing an additional 329,974 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 400 shares of the stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $500.50, for a total transaction of $200,200.00. Following the sale, the chief executive officer owned 113,762 shares in the company, valued at $56,937,881. This represents a 0.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock worth $14,182,963 over the last quarter. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Down 0.2%

Thermo Fisher Scientific stock traded down $1.08 during midday trading on Friday, hitting $480.02. 4,241,401 shares of the stock were exchanged, compared to its average volume of 1,433,914. The company has a 50 day moving average price of $472.01 and a two-hundred day moving average price of $450.02. The firm has a market cap of $181.26 billion, a P/E ratio of 27.76, a P/E/G ratio of 2.57 and a beta of 0.75. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $623.77. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. The company had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company's revenue was up 2.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.95%.

Analysts Set New Price Targets

TMO has been the topic of several research reports. Barclays upgraded shares of Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and increased their price target for the company from $490.00 to $550.00 in a research report on Thursday, September 11th. Evercore ISI lowered their price target on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 8th. Wells Fargo & Company lowered their price target on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a research report on Thursday, July 24th. Robert W. Baird increased their price target on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a research report on Thursday, July 24th. Finally, Scotiabank upgraded shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price target on the stock in a research report on Friday, July 11th. Sixteen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $588.35.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.